new_0222_0346|TPTX|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0346|TPTX|1|Turning Point Therapeutics Inc Total Current Assets (Quarterly) (USD)|Turning Point Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Turning Point Therapeutics Inc Inventories (Quarterly) (USD)|Turning Point Therapeutics Inc Net PP&E (Quarterly) (USD)|Turning Point Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Turning Point Therapeutics Inc Total Liabilities (Quarterly) (USD)|Turning Point Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Turning Point Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Turning Point Therapeutics Inc Total Deposits (Quarterly) (USD)|Turning Point Therapeutics Inc Book Value (Quarterly) (USD)|Turning Point Therapeutics Inc Retained Earnings (Quarterly) (USD)|Turning Point Therapeutics Inc Treasury Stock (Quarterly) (USD)|Turning Point Therapeutics Inc EV to Revenues|Turning Point Therapeutics Inc EV to Earnings|Turning Point Therapeutics Inc EV to Free Cash Flow|Turning Point Therapeutics Inc EV to Assets (Quarterly)|Turning Point Therapeutics Inc PS Ratio|Turning Point Therapeutics Inc PE Ratio|Turning Point Therapeutics Inc Price to Book Value|Turning Point Therapeutics Inc PEG Ratio|Turning Point Therapeutics Inc Debt to Equity Ratio|Turning Point Therapeutics Inc Dividend Yield|Turning Point Therapeutics Inc Shareholder Yield (TTM)|Turning Point Therapeutics Inc Percent of Shares Outstanding Short|Turning Point Therapeutics Inc Total Receivables (Quarterly) (USD)|Turning Point Therapeutics Inc Total Payables (Quarterly) (USD)|Turning Point Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Turning Point Therapeutics Inc Return on Invested Capital|Turning Point Therapeutics Inc Quality Ratio Score|Turning Point Therapeutics Inc Momentum Score|Turning Point Therapeutics Inc Beta (1Y)|Turning Point Therapeutics Inc Sustainable Growth Rate (TTM)|Turning Point Therapeutics Inc Institutional Investor Ownership Percentage|Turning Point Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Turning Point Therapeutics Inc Total Employees (Annual)|Turning Point Therapeutics Inc EPS Diluted (Quarterly) (USD)|Turning Point Therapeutics Inc Shares Outstanding|Turning Point Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Turning Point Therapeutics Inc Ordinary Shares Number (Quarterly)|Turning Point Therapeutics Inc Payout Ratio|Turning Point Therapeutics Inc Quick Ratio (Quarterly)|Turning Point Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Turning Point Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Turning Point Therapeutics Inc Effective Tax Rate (TTM)|Turning Point Therapeutics Inc Return on Equity|Turning Point Therapeutics Inc Net Income (TTM) (USD)|Turning Point Therapeutics Inc Revenue (TTM) (USD)|Turning Point Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Turning Point Therapeutics Inc Revenue (Quarterly) (USD)|Turning Point Therapeutics Inc Gross Profit (Quarterly) (USD)|Turning Point Therapeutics Inc SG&A Expense (Quarterly) (USD)|Turning Point Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Turning Point Therapeutics Inc Net Income (Quarterly) (USD)|Turning Point Therapeutics Inc Net Interest Income (Quarterly) (USD)|Turning Point Therapeutics Inc Price (USD)|Turning Point Therapeutics Inc Total Return Price (USD)|Turning Point Therapeutics Inc Enterprise Value (USD)|Turning Point Therapeutics Inc 30-Day Average Daily Volume|Turning Point Therapeutics Inc 1 Year Price Returns (Daily)||
new_0222_0346|TPTX|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0346|TPTX|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0346|TPTX|5|91.2727272727|91.2727272727|0|91.2727272727|0|91.2727272727|91.2727272727|91.2727272727|0|91.2727272727|91.2727272727|0|0|92|6.91946308725|91.25|0|0|6.92753623188|0|91.25|1.44803370787|92|15.2575757576|0|91.2727272727|91.2727272727|92|0|32.1052631579|30.5238095238|92|0|91.3571428571|92.7|91.3571428571|31.1666666667|0|91.2727272727|92|91.25|91.3571428571|91.3846153846|0|92|91.2727272727|0|0|91.25|0|91.3571428571|91.3571428571|91.3571428571|91.5|6.96621621622|6.96621621622|6.96621621622|6.95774647887|1.44565217391||
new_0222_0346|TPTX|6|11|11|0|11|0|11|11|11|0|11|11|0|0|1|149|4|0|0|138|0|4|712|1|66|0|11|11|1|0|19|21|1|0|14|10|14|30|0|11|1|4|14|13|0|1|11|0|0|4|0|14|14|14|2|148|148|148|142|460||
new_0222_0346|TPTX|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0346|TPTX|201803||||||||||||||||||||||||||||||||||14.938||-0.3168||||||-0.3168|||||||||0.516|-4.733|-4.733|0.127|||||||
new_0222_0346|TPTX|201806||||||||||||||||||||||||||||||||||14.938||-0.3372||||||-0.3372|0||||||||0.803|-5.037|-5.037|0.135|||||||
new_0222_0346|TPTX|201809||||||||||||||||||||||||||||||||||14.938||-0.4015||||||-0.4015|0||||||||1|-5.997|-5.997|0.132|||||||
new_0222_0346|TPTX|201812|101.523|101.029||1||151.686|5.322|146.364||-48.406|-50.753|||||||||||||||1.494|0.001|||||||14.938||-0.6037|||27.7577|||-0.6037|0|||-24.785|||||2.259|-9.018|-9.018||||||||
new_0222_0346|TPTX|201903|91.359|90.011||2.487||155.503|8.122|147.381||-60.005|-64.3||||-26.1772|||||||0||0.1116||2.697|0.001|||||||27.7577|63|-0.488|29.6547||27.7577|||-0.488|-0.022|||-33.599|||||3.614|-13.547|-13.547||29.37|29.37|747.4377|302792.1333||38.8|
new_0222_0346|TPTX|201906|255.168|250.17||2.204||9.53|7.888|1.642||247.915|-81.442||||-39.5506||||5.032|||0||3.7661||4.086|0.034|||||||24.4798|77|-0.7|31.2974||31.2974|||-0.7|-175.129|||-45.704|||||4.743|-17.142|-17.142||38.92|38.92|1129.2889|194807.1333||39.49|54.53
new_0222_0346|TPTX|201909|429.37|423.575||6.945||15.864|11.72|4.144||420.524|-101.925||||-28.9722||||5.8124|||0||6.3532||3.811|0.004|||||||32.3128|87|-0.63|35.8392||35.8392|||-0.63|-190.186|||-60.19|||||5.5|-20.483|-20.483||36.9|36.9|1172.5351|309190.4667||36.64|56.22
new_0222_0346|TPTX|201912|414.947|409.151||7.182||17.851|14.032|3.819||404.351|-122.884||||-34.1374||||5.5327|||0||6.2878||2.15|0.004|||||||35.9628|95|-0.58|35.9151||35.9151|||-0.58|0.681|||-72.131|||||5.924|-20.959|-20.959||60.63|60.63|1795.8675|633740.5||58.5|49.57
new_0222_0346|TPTX|202003|389.396|380.782||6.88||14.642|11.155|3.487||381.707|-183.602||||-21.1719||||4.2029|||0||8.4364||1.846|0.004|||10|1.2415|||35.9194|102|-1.69|35.9222||35.9222|||-1.69||||-119.302|||||39.857|-60.718|-60.718||42.1|42.1|1259.748|363767.8|48.0172|53.37|63.81
new_0222_0346|TPTX|202006|718.876|710.43||6.475||14.597|11.449|3.148||710.827|-215.095||||-31.5217||||3.8317|||0||6.7794||1.33|0.005|||10|1.419|||38.6032|109|-0.82|42.1689||42.1689|||-0.82|-351.611|||-133.653|||||8.578|-31.493|-31.493||64.59|64.59|2446.0854|509579.6667|58.6978|60.43|79.43
new_0222_0346|TPTX|202009|718.163|711.388||6.202||23.045|20.256|2.789||701.588|-232.8||||-33.4509|4.1074|||5.2531||0|0||8.9014||4.552|0.005|||8|1.5427|||42.1858|130|-0.42|42.2134||42.2134||35.1199|-0.42|0|||-130.875|||25||11.326|-17.705|-17.705||88.55|88.55|2811.5165|391565.8333|132.3404|100.08|104.58
new_0222_0346|TPTX|202012|1130.679|1122.508||5.961||26.815|24.392|2.423||1109.898|-280.176||||-82.7451|4.2306|||8.6864||0|0||4.5139||5.225|0.005|||9|1.3062|||46.6308|142|-1.02|48.6785||48.6785||46.0195|-1.02|-433.858|||-157.292|||||13.664|-47.376|-47.376||120.31|120.31|5382.9023|324529.8667|95.6173|128.07|117.28
new_0222_0346|TPTX|202103|1121.912|1114.777||5.565||26.419|24.371|2.048||1101.165|-315.68||||-38.9049|3.1317|||3.9578||0|0||4.8679||6.784|0.005|||8|0.8511|||48.9204|169|-0.73|49.117||49.117||45.7419|-0.73||||-132.078|||25.205||19.991|-35.504|-35.504||89.5|89.5|3270.2326|355928.6|111.8003|78.26|68.86
new_0222_0346|TPTX|202106|1091.42|1077.806||9.479||35.413|31.895|3.518||1067.507|-371.953|||-17.6958|-36.5359|2.5167|||3.3867||0|0|-11.2587|6.4757||7.088|0.005|-15.764||2|0.3713|-16.7191||49.2044||-1.14|49.3917||49.3917|0|33.7923|-1.14|0||-16.7191|-156.858|||5.164||17.171|-56.273|-56.273||75.87|75.87|2614.5825|575869.8667|20.7927|61|77.02
new_0222_0346|TPTX|202109|1047.141|1036.014||9.823||41.648|38.753|2.895||1017.337|-438.278|||-10.9496|-26.1208|2.1246|||3.2394||0|0|-13.2036|4.5797||3.188|0.005|-20.5581||4|0.8284|-20.5581||49.4265|237|-1.34|49.4642||49.4642|0|26.7338|-1.34|0||-20.5581|-205.478|||0.46||18.224|-66.325|-66.325||69.99|69.99|2380.2599|282599.4667|-23.9583|41.64|38.06
new_0222_0346|TPTX|202112|||||||||||||||-10.0965||||2.3642|||0||4.4674||||||1|-0.7678||||||||||||||||||||||||48.61|48.61|1369.1845|537903.5|-60.8535|38.08|34.72